Skip to main content

Home/ Groups/ OARS funding Cancer
MiamiOH OARS

PA-18-818: Administrative Supplements for Validation Studies of Analytical Methods for ... - 0 views

  •  
    The reproducibility and comparability of research on dietary supplements is enhanced by rigorous analytical characterization of key experimental materials and the publication of validated analytical methods that accurately and precisely characterized and quantify constituents in dietary supplement ingredients and products. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods. The methods proposed for validation must be used to identify and quantify dietary supplement-relevant chemical constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (e.g., urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grant's specific aims. Candidate constituents for quantitative method validation studies include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.
MiamiOH OARS

NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (U... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Minority/Underserved Community Sites" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCORP is a community-based research network that: Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials; Incorporates the needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups; Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN); Integrates cancer disparities research within the community network. NCORP consists of three components each with its own FOA: NCORP Research Bases; NCORP Community Sites; and NCORP Minority/Underserved Community Sites (covered by this FOA). The NCORP Minority/Underserved Community Sites will accrue diverse patients/participants to NCI-approved, cancer control, prevention, and care delivery research studies designed by NCI's NCORP Research Bases as well as treatment trials within the National Clinical Trials Network Groups (NCTN).
MiamiOH OARS

American Gastroenterological Association - 0 views

  •  
    Sponsored by the R. Robert and Sally D. Funderburg Charitable Trust, the annual award is designed to support an established investigator in the field of gastric biology whose research enhances our understanding of gastric cancer pathobiology and leads to its prevention or the development of a cure for the disease. The recipient will be selected based on novelty, feasibility, and significance of his/her proposal.
MiamiOH OARS

PA-18-821: Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - C... - 0 views

  •  
    The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s).
MiamiOH OARS

DoD Kidney Cancer, Translational Research Partnership Award - 0 views

  •  
    The FY18 KCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. It should be clear that both have had equal intellectual input in the design of the research project. Multi-institutional partnerships are encouraged. At least one member of the partnership must have experience either in kidney cancer research or kidney cancer patient care. Inclusion of experts from outside the kidney cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.
MiamiOH OARS

DoD Kideny Cancer, Idea Development Award - 0 views

  •  
    The FY18 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Personnel on the proposed team should have a strong background in kidney cancer research. The anticipated direct costs budgeted for the entire period of performance for an FY18 KCRP Idea Development Award will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
MiamiOH OARS

DoD Kidney Cancer, Concept Award - 0 views

  •  
    The FY18 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.
MiamiOH OARS

DoD Kideny Cancer, Technology Development Award - 0 views

  •  
    The KCRP Technology Development Award is a product-driven award mechanism intended to advance the development of technologies to aid kidney cancer clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life. Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems. Applications must describe how the technology will enhance the existing knowledge of kidney cancer.
MiamiOH OARS

Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Tri... - 0 views

  •  
    The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s). Applicants are strongly encouraged to discuss potential requests with the NCI scientific contacts listed below.
MiamiOH OARS

Stand Up To Cancer T-Cell Lymphoma Dream Team Translational Research Grant - 0 views

  •  
    Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.
MiamiOH OARS

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA solicits encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.
MiamiOH OARS

DoD Prostate Cancer, Impact Award - 0 views

  •  
    The Impact Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues, and ultimately make major advances toward eliminating death from prostate cancer and enhancing the well-being of Service members, Veterans, and all men experiencing the impact of the disease. The critical components of this award mechanism are:
MiamiOH OARS

DoD Prostate Cancer, Idea Development Award - 0 views

  •  
    * Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Multidisciplinary projects are especially encouraged.
MiamiOH OARS

Prostate Cancer, Early Investigator Research Award - 0 views

  •  
    * Principal Investigator: The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2019.

MiamiOH OARS

Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to encourage applicants to leverage existing datasets and employ new and advanced analysis techniques to answer scientific questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.
MiamiOH OARS

RFA-CA-18-013: Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvir... - 0 views

  •  
    The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.
    This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for well-developed research projects using the NIH R01 funding mechanism. The companion FOA, RFA-CA-18-014, is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.
MiamiOH OARS

Mark Foundation for Cancer Research Invites Proposals for Emerging Leaders Awards | RFP... - 0 views

  •  
    The Mark Foundation for Cancer Research funds groundbreaking research that integrates discoveries in biology with innovative technology to deliver breakthroughs to patients.
    To advance this mission, the foundation is inviting proposals for its Emerging Leaders Awards program, which provides support to early-career investigators engaged in high-impact, high-risk cancer research. Through the annual program, the foundation will award three-year grants of $750,000. The award is intended to support projects for which other sources of funding are not readily available from traditional funding mechanisms or for a separate innovative endeavor that will enhance the PI's current research portfolio.
    Eligible applicants must hold an MD, PhD, MD/PhD, or the equivalent at a U.S. nonprofit academic institution and be within three to eight years of their initial independent appointment. In addition, applicants must have a demonstrated ability to obtain independent funding for their lab (e.g., one or two grants such as NIH/R01, NSF/CAREER, or equivalent multi-year awards).
MiamiOH OARS

LARGE-SCALE T CELL IMMUNE EPITOPE DISCOVERY - Federal Business Opportunities: Opportuni... - 0 views

  •  
    The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams, whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, and rejection of, or tolerance to, transplanted cells/organs/tissues. The discovery of epitopes associated with T cell responses to commensals and how they may be altered by the inflammatory state will also be supported by this solicitation. Validation of these epitopes and defining their role in immune protection or immune-mediated pathogenesis in humans is required. Investigators may include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), clinicians with expertise in the target autoimmune diseases, or clinicians with expertise in transplantation, as appropriate. This program will not support studies related to HIV/AIDS, or allergen epitopes, including those which are infection-related.
MiamiOH OARS

PREVENT Cancer Preclinical Drug Development Program - Federal Business Opportunities: O... - 0 views

  •  
    The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of
    (1) in vivo development/animal efficacy/biomarker development,
    (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and
    (3) toxicology/pharmacology testing.
MiamiOH OARS

Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional) - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.
1 - 20 of 551 Next › Last »
Showing 20 items per page